logo
ProjectForthcoming

NeuroLens - Ultra-high Resolution Detection of Pathologic Protein Aggregation in the Human Brain

Forthcoming · Austria, Germany, Spain, Netherlands, Belgium

Source: EU Funding & Tenders Portal

Progressive supranuclear palsy (PSP) is a fatal, rare 4-repeat tauopathy for which no disease-modifying therapy exists and no validated early biomarker is available. Patients endure a diagnostic odyssey exceeding four years after symptom onset, driven by poor early-stage sensitivity of clinical criteria and the inability of conventional PET systems to resolve relevant small subcortical nuclei. As

Status
Prospective
Sector
Hospital
Location
Austria, Germany, Spain, Netherlands, Belgium
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about NeuroLens - Ultra-high Resolution Detection of Pathologic Protein Aggregation in the Human Brain

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “NeuroLens - Ultra-high Resolution Detection of Pathologic Protein Aggregation in the Human Brain” is an infrastructure initiative in the Hospital sector, located in Austria, Germany, Spain, Netherlands, Belgium. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Progressive supranuclear palsy (PSP) is a fatal, rare 4-repeat tauopathy for which no disease-modifying therapy exists and no validated early biomarker is available. Patients endure a diagnostic odyssey exceeding four years after symptom onset, driven by poor early-stage sensitivity of clinical criteria and the inability of conventional PET systems to resolve relevant small subcortical nuclei. As tau-targeting therapies are now entering clinical development, accurate early staging is essential to enable biomarker-guided therapeutic trials in PSP and in broader tauopathies including Alzheimer's disease. NeuroLens addresses this unmet need by generating robust, EU Medical Device Regulation (MDR)-compliant clinical evidence for a breakthrough orphan PET/MRI insert designed for 3-Tesla scanners. The device achieves sub-millimetre effective spatial resolution and more than twice the sensitivity of standard whole-body PET systems, enabled by high-resolution 3D Time-of-Flight detectors with AI-assisted Depth-Of-Interaction determination and a physics-informed AI reconstruction pipeline integrating simultaneous 4D MRI motion fields and multi-frame super-resolution. Using the orphan-designated tau tracer [18F]PI-2620, a prospective, blinded, multinational diagnostic accuracy study will enrol 180 early-stage PSP participants across Germany and Spain with 18-month longitudinal follow-up. Primary targets include a diagnostic sensitivity gain of at least 15% over standard PET and a reduction in median diagnostic delay of at least 30%. The project will finalise a CE-submission-ready MDR Annex XIV/XV dossier, release FAIR datasets and open-source software, and deliver harmonised adoption kits for EU-wide rollout. The interdisciplinary consortium of eight partners from five EU Member States integrates imaging engineering SMEs, expert clinical hubs, and an SSH partner to ensure a patient-centred, gender-sensitive approach throughout.

Location

Country

Austria, Germany, Spain, Netherlands, Belgium

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital

Article published date

2026-11-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project